Lersivirine

SKU: orb1299580

Description

Lersivirine (UK-453061) is a next-generation NNRTI developed for the treatment of HIV-1 infection. It has demonstrated potent antiviral activity in vitro and has been evaluated in clinical trials for its efficacy against both wild-type and drug-resistant virus strains.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 473921-12-9
• MW: 310.35
• Purity: 99.26% (May vary between batches)
• Formula: C₁₇H₁₈N₄O₂
• SMILES: CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N
• Target: HIV Protease,Reverse Transcriptase
• Solubility: DMSO:50 mg/mL (161.11 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (8.06 mM)

Bioactivity

• Target IC50:
  NNRT:119 nM (IC50)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NNRTI, NNRTI-resistant, inhibit, Inhibitor, non-nucleoside reverse transcription, Lersivirine, Lersivirine(UK 453061), HIV, HIVProtease, HIV virus, HIV Protease, Human immunodeficiency virus, resistant strain, ReverseTranscriptase, Reverse Transcriptase, UK 453061, UK453061, UK-453061

Compound Identifiers

PubChem CID

16739244